METHODS FOR DETERMINING RESPONSIVENESS TO TYK2 INHIBITORS
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Nov 28, 2024
app pub date -
Sep 29, 2022
filing date -
Sep 29, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed are methods of treating psoriatic arthritis in a subject comprising administering to the subject a TYK2 inhibitor (e.g., deucravacitinib), wherein the methods depend on whether the subject exhibits certain levels of specific proteins in the blood (e.g., plasma or serum) prior to or early during administration of the TYK2 inhibitor. Also disclosed are methods for selecting subjects suffering from psoriatic arthritis for treatment with a TYK2 inhibitor, wherein subjects are selected based on the level of one or more proteins in the blood prior to treatment with a TYK2 inhibitor.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully